Tretinoin
NDC 53002-8101
Product Information
Tretinoin is a ANDA-approved product labeled by Rpk Pharmaceuticals, Inc.. This medication is used to treat acne. It is supplied as a product. This product entry covers the primary NDC 53002-8101 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 53002-8101?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TRETINOIN (UNII: 5688UTC01R)
- TRETINOIN (UNII: 5688UTC01R) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- STEARIC ACID (UNII: 4ELV7Z65AP)
- ISOPROPYL MYRISTATE (UNII: 0RE8K4LNJS)
- POLYOXYL 40 STEARATE (UNII: 13A4J4NH9I)
- STEARYL ALCOHOL (UNII: 2KR89I4H1Y)
- XANTHAN GUM (UNII: TTV12P4NEE)
- SORBIC ACID (UNII: X045WJ989B)
- BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 106302 - tretinoin 0.025 % Topical Cream
- RxCUI: 106302 - tretinoin 0.25 MG/ML Topical Cream
* Please review the full disclaimer at the bottom of this page.
Patient Education
Tretinoin Topical
Tretinoin (Altreno, Atralin, Avita, Retin-A) is used to treat acne. Tretinoin is also used to reduce fine wrinkles (Refissa and Renova) and to improve spotty discoloration (Renova) and rough feeling skin (Renova) when used along with other skin care and sunlight avoidance programs. Tretinoin is in a class of medications called retinoids. It works by promoting peeling of affected skin areas and unclogging pores.
[Learn More]
* Please review the full disclaimer at the bottom of this page.